# Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

> **NCT00276302** · PHASE1 · COMPLETED · sponsor: **Infinity Pharmaceuticals, Inc.** · enrollment: 63 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors
- Soft Tissue Sarcomas

## Interventions

- **DRUG:** IPI-504

## Key facts

- **NCT ID:** NCT00276302
- **Lead sponsor:** Infinity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2011-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276302, "Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00276302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*